Santamaria A, et al. - In view of the failure of previous studies to show a clear reduction of gestational diabetes mellitus (GDM) complications, researchers evaluated clinical and metabolic outcomes in women at risk for GDM supplemented with myo-inositol since first trimester. They performed a secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled), in which women at risk for GDM (a parent with type 2 diabetes, obese or overweight) were supplemented with myo-inositol (4g/day) throughout pregnancy. In this work, women at risk for GDM demonstrated a reduction in the rate of GDM and in the risk of preterm birth and macrosomia in association with myo-inositol treatment in early pregnancy.